You are here: Industry Insights > Mitsubishi Tanabe Pharma

News List

BioInvent receives €0.75 M under Mitsubishi Tanabe Pharma partnership biospectrumasia
April 29, 2019
The license agreement with Mitsubishi Tanabe Pharma covers the development of antibodies from the n-CoDeR antibody library.
Salix partners with Mitsubishi Tanabe Pharma to market IBD drug biospectrumasia
April 28, 2019
Collaboration to develop and commercialize late stage investigational S1P modulator for the treatment of Inflammatory Bowel Disease (IBD)
BioInvent receives €0.75 M under Mitsubishi Tanabe Pharma partnership biospectrumasia
April 28, 2019
The license agreement with Mitsubishi Tanabe Pharma covers the development of antibodies from the n-CoDeR antibody library.
Salix Announes License Agreement with Mitsubishi Tanabe Pharma to Develop, Commercialize MT-1303 americanpharmaceuticalreview
April 26, 2019
Salix Pharmaceuticals announced its affiliate has entered into an exclusive licensing agreement with Mitsubishi Tanabe Pharma to develop and commercialize MT-1303 (amiselimod) ...
Payers line up to back Mitsubishi Tanabe's pricey new ALS therapy Radicava fiercepharma
August 17, 2017
Mitsubishi Tanabe Pharma America's Radicava is the second-ever FDA-approved ALS med.
Mitsubishi Tanabe Pharma to buy NeuroDerm for $1.1bn pharmaceutical-technology
July 27, 2017
Japan’s Mitsubishi Tanabe Pharma (MTPC) has entered a new definitive agreement to acquire all of the outstanding shares of Israel-based pharmaceutical company NeuroDerm for $1.1bn in cash.
Mitsubishi Tanabe Pharma gets approval for Canalia combination tablets in Japan pharmaceutical-technology
July 05, 2017
Japanese firm Mitsubishi Tanabe Pharma’s combination drug application has received approval from the Japanese Ministry of Health, Labour and Welfare (MHLW) for the manufacturing and sale of Canalia combination tablets for the treatment of an indication of